Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Link between A2M gene and Alzheimer's disputed:

This article was originally published in Clinica

Executive Summary

Polymorphisms of the alpha-2-macroglobulin (A2M) gene do not appear to be associated with late-onset Alzheimer's disease, contrary to some reports, claims a team of Dutch researchers in the September issue of Neurology. Researchers at the Erasmus Medical Centre in Rotterdam studied two A2M polymorphisms in 344 patients with late-onset disease and 242 controls. There was no observable genotypic or allelic association with late-onset disease, although one of the polymorphisms was significantly less common in patients of Asian origin.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT074759

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel